Alkermes plc (ALKS)
| Market Cap | 4.80B |
| Revenue (ttm) | 1.52B |
| Net Income (ttm) | 338.83M |
| Shares Out | 165.12M |
| EPS (ttm) | 2.02 |
| PE Ratio | 14.43 |
| Forward PE | 14.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,747,692 |
| Open | 30.22 |
| Previous Close | 31.01 |
| Day's Range | 28.67 - 30.37 |
| 52-Week Range | 25.17 - 36.45 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 42.46 (+46.21%) |
| Earnings Date | Oct 28, 2025 |
About ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable su... [Read more]
Financial Performance
In 2024, Alkermes's revenue was $1.56 billion, a decrease of -6.36% compared to the previous year's $1.66 billion. Earnings were $367.07 million, an increase of 3.18%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ALKS stock is "Strong Buy." The 12-month stock price target is $42.46, which is an increase of 46.21% from the latest price.
News
Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal
Avadel Pharmaceuticals plc (NASDAQ: AVDL) on Friday received an unsolicited proposal from H. Lundbeck A/S for up to $23.00 per ordinary share.
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
Alkermes reviewing options after Lundbeck makes unsolicited bid for Avadel
Alkermes said on Friday it is reviewing its options with advisers after Avadel Pharmaceuticals disclosed it had received an unsolicited takeover proposal from Danish pharmaceutical company Lundbeck.
Alkermes Response to Avadel Announcement
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULAT...
Avadel Receives Unsolicited Proposal from Lundbeck
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FR...
Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study
Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in narcolepsy type 2 (NT2).
Alkermes' narcolepsy drug meets main goal in a mid-stage trial
Alkermes said on Wednesday its experimental narcolepsy drug met the main goals in a mid-stage study.
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the...
Alkermes to Participate in Two Upcoming Investor Conferences
DUBLIN , Nov. 6, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2025 Healthcare Conference Date/Time: Th...
FORM 8.1(a) & (b) (Opening Position Disclosure)
DUBLIN , Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS): IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 202...
Alkermes plc (ALKS) Q3 2025 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS) Q3 2025 Earnings Call October 28, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Ch...
Alkermes plc Reports Third Quarter 2025 Financial Results
— Third Quarter Revenues of $394.2 Million — — GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 — — Company Raises 2025 Financial Expectations — DUBLIN , Oct. 28,...
Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz
On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire Avadel Pharmaceuticals plc (NASDAQ:AVDL) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion.
Alkermes plc (ALKS) M&A Call Transcript
Alkermes plc (NASDAQ:ALKS) M&A Call October 22, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO ...
Alkermes to acquire Avadel for up to $2.1 billion
Alkermes said on Wednesday it will acquire Avadel Pharmaceuticals for up to $2.1 billion gaining access to the company's approved excessive daytime sleepiness drug.
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIO...
Alkermes to Report Third Quarter Financial Results on October 28, 2025
DUBLIN , Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m.
Alkermes Appoints Joshua Reed as Chief Financial Officer
DUBLIN , Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept.
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/o...
Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)
Alkermes plc (NASDAQ:ALKS) World Sleep Congress 2025 Conference September 8, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Rich...
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses – – Ali...
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity,...
Alkermes: A More Than Solid Quarter
Alkermes plc is a mid-cap and quite profitable commercial-stage biopharma company, and we are revisiting it today for the first time in a year. The company just reported Q2 financial results, with pro...